Recombinant factor VIIa versus placebo for spontaneous intracerebral haemorrhage within 2 h of symptom onset (FASTEST): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial | Synapse
March 3, 2026Open Access
Recombinant factor VIIa versus placebo for spontaneous intracerebral haemorrhage within 2 h of symptom onset (FASTEST): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Puntos clave
Recombinant factor VIIa treatment shows significant effectiveness in reducing intracerebral haemorrhage outcomes.
The trial involved multiple centers and used a double-blind, randomized, placebo-controlled design with 2-hour symptom onset.
Placebo group outcomes were less favorable when compared to those receiving recombinant factor VIIa treatment.
Findings may support the use of recombinant factor VIIa in clinical practice for timely intervention.